



Adverum Biotechnologies to Present at the 2018 Jefferies Global Healthcare Conference

June 4, 2018

MENLO PARK, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced today that Leone Patterson, interim president and chief executive officer of Adverum, will present at the Jefferies Global Healthcare Conference.

Event: Jefferies Global Healthcare Conference

Date: June 8, 2018

Time: 12:30 – 12:55 p.m. ET

Location: New York, NY

A live and replay audio webcast of the presentation will be available from Adverum's website at <http://investors.adverum.com>.

About Adverum Biotechnologies, Inc.

Adverum is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum's core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development. For more information please visit www.adverum.com.

Adverum Contact:

Leone Patterson

Interim President and Chief Executive Officer

650-665-7222

lpatterson@adverum.com

 [Primary Logo](#)

Source: Adverum Biotechnologies, Inc.